Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Demis Hassabis
AddedFeb 13, 2024
UpdatedJun 28, 2026
Demis Hassabis

Demis Hassabis

Founder and CEO, Isomorphic Labs

Demis Hassabis's Career

Isomorphic Labs
Isomorphic Labs

London, GB

Founder and CEO

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Demis Hassabis's Career

Isomorphic Labs
Isomorphic Labs
$2.8B2021London, GB
Founder and CEO

Recent news

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2BTechCrunch · 2026
Isomorphic Labs announces Series B investment roundIsomorphic Labs · 2026
Isomorphic Labs Enters into a Research Collaboration with Johnson & JohnsonIsomorphic Labs · 2026

Leadership at Isomorphic Labs

Ben WolfBen WolfChief Medical Officer
Sarah SkerrattSarah SkerrattChief Research Officer
Beverley MallonBeverley MallonChief People Officer
Sarah KormanSarah KormanChief Business and Legal Officer
Miles CongreveMiles CongreveChief Scientific Officer
Max JaderbergMax JaderbergPresident

Similar to Isomorphic Labs

Insilico MedicineInsilico MedicineNew York City, NY, USDrug Discoveryest. 2014Insilico MedicineNew York City, NY, US · est. 2014

Insilico Medicine: A global AI biotech firm dedicated to extending human productive longevity.

$401.3M278
InherentInherentLondon, England, GBest. 2026InherentLondon, England, GB · est. 2026

Inherent is a London-based AI lab building recursively self-improving AI for scientific discovery.

Seed · $50M
Verge GenomicsVerge GenomicsSan Francisco, CA, USDrug Developmentest. 2015Verge GenomicsSan Francisco, CA, US · est. 2015

Verge Genomics accelerates drug development for neuro diseases using AI and human data.

$134.1M83
Relay TherapeuticsRelay TherapeuticsCambridge, MA, USDrug Discoveryest. 2016Relay TherapeuticsCambridge, MA, US · est. 2016

US-based Relay Therapeutics revolutionizes drug discovery with precision medicine and advanced computational power.

Public · $1.2B327

Demis Hassabis's Co-Investors

RichardRichardCo-invested · Cosmos Innovation Series ATomaso PoggioTomaso PoggioCo-invested · Cosmos Innovation Series ARichardRichardCo-invested · Cosmos Innovation Series AMatt MullenwegMatt MullenwegCo-invested · Entrepreneur First Series CPatrick O'ShaughnessyPatrick O'ShaughnessyCo-invested · Entrepreneur First Series CTaavet HinrikusTaavet HinrikusCo-invested · Entrepreneur First Series CNat FriedmanNat FriedmanCo-invested · Entrepreneur First Series CRob BishopRob BishopCo-invested · Entrepreneur First Series C

People Similar to Demis Hassabis

Nate KushmanNate KushmanFounder · ÜbubuAndrey ShekaAndrey ShekaCo-Founder · ExamusAgustin CaverzasiAgustin CaverzasiFounder · Anyone AISam AltmanSam AltmanFounder · LooptTian WuTian WuCo-Founder · Landing AI